DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

DBVT has been the topic of several other reports. JMP Securities reaffirmed a “market outperform” rating and issued a $25.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th. HC Wainwright boosted their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Stock Up 27.2 %

Shares of NASDAQ DBVT opened at $3.90 on Friday. The stock has a market cap of $376.35 million, a price-to-earnings ratio of -4.33 and a beta of 0.66. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $10.70. The company’s fifty day moving average is $3.42 and its 200-day moving average is $4.18.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.